Cargando…

Improved affinity AFP-specific T cell receptor for hepatocellular carcinoma

Detalles Bibliográficos
Autores principales:	Gerry, Andrew B, Pumphrey, Nicholas J, Docta, Roslin Y, Brewer, Joanna E, Bennett, Alan D, Jakobsen, Bent K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990298/ http://dx.doi.org/10.1186/2051-1426-1-S1-P10

Ejemplares similares

Preclinical safety testing of an affinity-optimised MAGE-A10 T cell receptor for adoptive T cell therapy
por: Gerry, Andrew, et al.
Publicado: (2015)

Tuning T‐Cell Receptor Affinity to Optimize Clinical Risk‐Benefit When Targeting Alpha‐Fetoprotein–Positive Liver Cancer
por: Docta, Roslin Y., et al.
Publicado: (2019)

Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT
por: Rapoport, Aaron P, et al.
Publicado: (2013)

T cell receptor binding affinity governs the functional profile of cancer-specific CD8(+) T cells
por: Tan, M P, et al.
Publicado: (2015)

Human leucocyte antigen class I‐redirected anti‐tumour CD4(+) T cells require a higher T cell receptor binding affinity for optimal activity than CD8(+) T cells
por: Tan, M. P., et al.
Publicado: (2016)

Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma
por: Park, Sang Joon, et al.
Publicado: (2017)

Cancer-specific T cell receptor isolation for cancer immunotherapy
por: Baker, Debbie Emma, et al.
Publicado: (2015)

Tumor-derived alpha-fetoprotein (tAFP) causes immune and metabolic dysfunction in monocyte-derived dendritic cells
por: Santos, Patricia M, et al.
Publicado: (2015)

T cell receptor affinity and avidity defines antitumor response and autoimmunity in T cell immunotherapy
por: Krogsgaard, Michelle, et al.
Publicado: (2013)

TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma
por: Mao, Liping, et al.
Publicado: (2017)

Alpha-Fetoprotein (AFP) and AFP-L3 Is Most Useful in Detection of Recurrence of Hepatocellular Carcinoma in Patients after Tumor Ablation and with Low AFP Level
por: Force, Madison, et al.
Publicado: (2022)

Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis
por: Wang, Xueying, et al.
Publicado: (2020)

The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma
por: Qi, Famei, et al.
Publicado: (2019)

Validation of combined AFP, AFP-L3, and PIVKA II for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients
por: Ren, Tianying, et al.
Publicado: (2023)

Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate
por: Border, Ellen C., et al.
Publicado: (2018)

The role of ERCC1 and AFP gene polymorphism in hepatocellular carcinoma
por: Huang, Yu-Liang, et al.
Publicado: (2019)

New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma
por: Wang, Ting, et al.
Publicado: (2020)

Co-expression networks identify distinct immune infiltrates in hepatocellular carcinoma
por: Chiang, Derek Y, et al.
Publicado: (2015)

Evaluation of novel immunocytokines that preferentially target high or intermediate affinity IL-2 receptors
por: Perez Horta, Zulmarie, et al.
Publicado: (2014)

Simple Clinical Metrics Enhance AFP to Effectively Identify Cirrhotic Patients With Complicating Hepatocellular Carcinoma at Various AFP Levels
por: Zhang, Xi, et al.
Publicado: (2020)

Identification of Plasma hsa_circ_0005397 and Combined With Serum AFP, AFP-L3 as Potential Biomarkers for Hepatocellular Carcinoma
por: Liu, Ruoyu, et al.
Publicado: (2021)

Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy
por: Simister, Philip C, et al.
Publicado: (2022)

The Tumor Targeted Superantigen ABR-217620 Selectively Engages TRBV7-9 and Exploits TCR-pMHC Affinity Mimicry in Mediating T Cell Cytotoxicity
por: Hedlund, Gunnar, et al.
Publicado: (2013)

Development and Validation of a Prognostic Nomogram in AFP-negative hepatocellular carcinoma
por: Wang, Xueping, et al.
Publicado: (2019)

Establishment and validation of nomogram model for the diagnosis of AFP-negative hepatocellular carcinoma
por: Liu, Long, et al.
Publicado: (2023)

ImmTACs: bi-specific TCR-anti-CD3 fusions for targeted tumour killing
por: Donnellan, Zoe, et al.
Publicado: (2015)

Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis
por: Liu, Siyu, et al.
Publicado: (2022)

Serum GP73 is complementary to AFP and GGT-II for the diagnosis of hepatocellular carcinoma
por: HOU, SI-CONG, et al.
Publicado: (2013)

LARP1 predict the prognosis for early-stage and AFP-normal hepatocellular carcinoma
por: Xie, Chan, et al.
Publicado: (2013)

Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma
por: Vongsuvanh, Roslyn, et al.
Publicado: (2016)

Serum AFU, 5’-NT and AFP as Biomarkers for Primary Hepatocellular Carcinoma Diagnosis
por: Junna, Zhu, et al.
Publicado: (2017)

A Logistic Regression Model for Noninvasive Prediction of AFP-Negative Hepatocellular Carcinoma
por: Luo, Chang-Liang, et al.
Publicado: (2019)

AFP-L3 for the diagnosis of early hepatocellular carcinoma: A meta-analysis
por: Zhou, Jian-Ming, et al.
Publicado: (2021)

Metabolomic biomarkers for the diagnosis and post-transplant outcomes of AFP negative hepatocellular carcinoma
por: Lin, Zuyuan, et al.
Publicado: (2023)

Process improvement and comparability analysis for engineered T cell manufacture
por: Melchiori, Luca, et al.
Publicado: (2014)

Early serum screening for hepatocellular-carcinoma in patients with hepatitis
por: Neguț, Alina Cristina, et al.
Publicado: (2014)

Deep phenotypic characterization of NY-ESO TCR engineered T cells and tumor in patients with advanced myeloma
por: Davila, Eduardo, et al.
Publicado: (2015)

AFP
Publicado: (2009)

The immunoglobulin CH1 constant region modulates antigen binding affinity and functional activities of the broadly neutralizing 2F5 HIV specific antibody
por: Tudor, Daniela, et al.
Publicado: (2010)

Chondroitin sulfate proteoglycan 4 specific chimeric antigen receptor therapy for pediatric solid tumors
por: Tschernia, Nicholas, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ui3o34i1i2uei4i2tk4g8n7il9